Performance of Detecting IgM Antibodies against Enterovirus 71 for Early Diagnosis

Feihai Xu1, Qiang Yan1, Hua Wang2, Jianjun Niu3, Liang Li2, Fengcai Zhu2, Shuizhen He3, Shiyin Zhang1, Mun-Hon Ng1, Ningshao Xia1*

1 National Institute of Diagnostics and Vaccine Development in Infectious Disease, Xiamen University, Xiamen, China, 2 Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China, 3 Xiamen Center for Disease Control and Prevention, Xiamen, China

Abstract

Enterovirus 71 (EV71) infection is more likely to induce severe complications and mortality than other enteroviruses. Methods for detection of IgM antibody against EV71 had been established for years, however, the performance of the methods in the very early diagnosis of EV71 infection had not been fully evaluated, which is especially meaningful because of the short incubation period of EV71 infection. In this report, the performance of an IgM anti-EV71 assay was evaluated using acute sera collected from 165 EV71 infected patients, 165 patients infected with other enteroviruses, and more than 2,000 sera from healthy children or children with other infected diseases. The results showed a 90% sensitivity in 20 patients who were in their first illness day, and similar sensitivity remained till 4 days after onset. After then the sensitivity increased to 95% to 100% for more than one month. The specificity of the assay in non-HFMD children is 99.1% (95% CI: 98.6–99.4), similar as the 99.9% specificity in healthy adults. The cross-reaction rate in patients infected with other non-EV71 enteroviruses was 11.4%. In conclusion, the data here presented show that the detection of IgM anti-EV71 by ELISA affords a reliable, convenient, and prompt diagnosis of EV71 infection.

Introduction

Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) are the principal pathogens of hand foot and mouth disease (HFMD). EV71 is of special concern because it is more likely to induce severe complications and mortality than other enteroviruses, and has become endemic in Southeast Asia for tens of years [1,2]. It has caused several wide spread epidemics in this region since 1997 and is expected to continue to do so in the future [3–6]. There is no effective anti-virus treatment for EV71 and control depends on prompt diagnosis and timely implementation of appropriate measures to contain the spread of the infection [7,8].

Laboratory diagnosis of EV71 relies mainly on detection of the viral genome by reverse transcription polymerase chain reaction or on virus isolation techniques [9–13]. However, these methods were unaffordable in most community clinics in developing countries in which most epidemics occurred. Tsao et al. (2002) showed and confirmed later by Wang et al. (2004) that IgM anti-EV71 was detectible in patients [14,15]. However, due to the very limited number of evaluated clinical samples in these studies, the diagnosis accuracy of IgM anti-EV71 test had not been well determined [16]. The aim of this study was to assess the performance of detecting IgM anti-EV71 for early diagnosis of patients with HFMD.

Materials and Methods

Ethic Statement

Written informed consent was obtained from each subject. Independent Ethics Committee approval was obtained from the Ethics Committee of the National Institute of Diagnostics and Vaccine Development in infectious diseases.

Study design

The sensitivity of the IgM anti-EV71 assay was evaluated in HFMD patients who were confirmed to be recently EV71 infection, and was classified by the days apart from the onset. The specificity of the assay was evaluated in children patients with confirming diagnosis of other respiratory diseases. The cross-reactivity of the assay was evaluated in HFMD patients infected by other enteroviruses.

Serum samples

A total of 376 serum samples were collected from HFMD patients, herpangina, aseptic meningitis, or encephalitis between March and September 2008. Of these samples, 221 were collected from 165 EV71-infected patients with the mean age of 2.6±2.1, 155 were from CA16-infected patients with the mean age of 2.7±2.5. The infection of EV71 or CA16 among these patients.
was determined by detection of the viral RNA by reverse transcript PCR. Twelve serum samples collected from patients infected by other enteroviruses (4 coxsackievirus A2, 1 coxsackievirus A4, 1 coxsackievirus B3, 2 coxsackievirus B4, 2 coxsackievirus B5, and 2 echovirus 6) were gifts from Dr. P. J. Chen of National Taiwan University, which were determined by virus isolation.

Control samples for this study included three groups. The first group included 120 sera from children patients with the following clinical features: Pneumonia (83 cases), Bronchitis (16), acute upper respiratory infections (15), and Influenza (12). The second group included 1907 stored sera from healthy children who received health examinations in with the mean age of 2.1±2.7. The third group included 807 sera from healthy adult blood donors. The EV71 neutralizing antibody titers of all control samples were less than 1:100. Twenty serum samples positive with IgM test in the acute phase is 94.1% (95% CI: 90.2–96.8). The mean sensitivity of the negative control was lower than 0.05, this was treated as 0.05. Levels of anti-EV71 IgM were expressed in S/CO value, which was calculated as the ratio of the OD value obtained with the test sample to the cutoff value of IgM test in the acute phase.

Neutralization test

Laboratory methods for measuring EV71 neutralizing antibody followed standard protocol for the neutralization test on microtiter plates [17,18]. Serum specimens were serially diluted two-fold (from 8 to 2048) and mixed with equal volume of EV71 (100 TCID50/50 μl) at 37°C for 60 min. The mixtures were incubated in replicate microplate cultures of human embryonic rhabdomyosarcoma (RD) cells. Cytopathic effects (CPE) were read under an inverted microscope after 2 to 7 days. Neutralizing antibody titer was defined as the highest dilution of serum that prevented the occurrence of CPE.

Detection of IgM anti-EV71

IgM anti-EV71 was detected using an IgM μ-chain capture enzyme-linked immunoabsorbant assay (ELISA) (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., China) according to manufacturer’s instruction. Briefly, 100 μl of dilution buffer were added to microplate wells pre-coated with anti-human IgM μ-chain, then 10 μl of serum samples were added and mixed tenderly, incubated at 37°C for 30 min, washed 5 times with washing buffer. Then 50 μl of the antigen solution, prepared by inactivating and fracturing of the cell free culture supernatant of an EV71 isolate JS/52-3/06, was added followed by 50 μl of a horseradish peroxidase (HRP)-conjugated mouse anti-EV71 monoclonal antibody, mixed, incubated for 30 min and then washed 5 times. 100 μl of TMB substrate was added then incubated at 37°C for 15 min before adding 50 μl 2N H2SO4 for terminating the reaction. The optical density (OD) was read at a wavelength of 450 nm with a reference filter of 620 nm. The cutoff value was calculated as 0.1+ mean OD value of the negative control. If the mean absorbance value of the negative control was lower than 0.05, this was treated as 0.05. Levels of anti-EV71 IgM was expressed in S/CO value, which was calculated as the ratio of the OD value obtained with the test sample to the cutoff value determined concurrently. A S/CO value not less than 1.0 indicated a positive result.

Table 1. List of primers designed for the specific amplification of EV71 and CA16.

| Primer name | Sequences(5'-3') | Position(nt) |
|-------------|----------------|--------------|
| EV71-F1     | 5'-AGAGCATGATTGAGACAGC-3' | 2607-2627 |
| EV71-R1     | 5'-RCCCTTCCTCYGTGTGTTC-3' | 3083-3063 |
| CA16-F1     | 5'-TCCAGACATGGAGACAGC-3' | 2457-2475 |
| CA16-R1     | 5'-TCCCTACTGTGCTAATGCT-3' | 3163-3144 |
| CA16-F2     | 5'-TGTGTGGACCACTACCTC-3' | 2649-2667 |
| CA16-R2     | 5'-TAGTGAACAACCTGCACCTT-3' | 2824-2805 |

Results

Table 2 compared the prevalence and mean levels of IgM anti-EV71 in serum samples collected from 165 EV71 infected patients at different times from 1 to 41 days after onset. The detection rate of IgM reached to 90% (18/20) in samples collected on the first day after onset, remained on this high level during the very early acute phase before the forth days after onset, and then increased to 95% to 100% for more than one month. The mean sensitivity of IgM test in the acute phase is 94.1% (95% CI: 90.2-96.8). The dynamic of IgM antibody level during acute phase was in consistent with the detection rate, as indicated by the S/CO values.

Table 3 compared the occurrence of IgM anti-EV71 in serum samples obtained from other enterovirus-infected patients or control subjects. IgM anti-EV71 was detected in 19 of 155 samples (12.3%) from CA16-infected patients which indicated the cross-reaction and 0 of 12 samples from patients infected with other enteroviruses. The mean S/CO value of the cross-reaction...
samples was 2.0 ± 1.4, which was significantly lower than that in positive samples from EV71-infected patients (mean = 10.8 ± 7.3). Among control subjects who were not infected by enteroviruses, the false positive results were found in 19 of 1907 samples (1.0%) from healthy children and 1 of 807 samples (0.12%) from healthy adults and absent in samples from patients with other childhood illnesses and the rheumatoid factor positive patients. The specificity of the assay was 98.7% (2990/3029, 95% CI: 98.2–99.1). Rheumatoid factor was not a confounder.

**Discussion**

Several countries in Asia have instituted surveillance to provide early warning of outbreaks, which are largely depended on the timely case reports with pathogenic diagnosis from community clinics [19,20]. Traditional laboratory diagnosis for EV71 is by cell culture followed by neutralization tests with serotype-specific antisera [9]. However, it requires weeks to obtain results. Consequently, molecular methods such as PCR have been developed to detect EV71 [10–13]. Unfortunately, these methods require expensive and specialized equipment and trained personnel, and can not be applied in most community clinics in developing world. IgM assays based on enzyme immunological techniques had been generally used for tens of years in most community clinics in many developing countries. The in-house IgM assays for diagnosis of acute EV71 infection had been established for years. However, the performance of the assays on early diagnosis of EV71 infected patients had not been fully evaluated. The results in this study showed a 90% sensitivity in patients who were in their first illness day, and similar sensitivity remained till 4 days after onset. After then the sensitivity increased to 95% to 100% for more than one month. Generally this sensitivity satisfies most of the demands for clinical early diagnosis as well as for early warning of outbreaks. The specificity of the assay in non-HFMD children is 99.1% (95% CI: 98.6–99.4), similar as the 99.9% specificity in healthy adults. It is noticed that substantial proportion (11.4%, 95% CI: 7.0–17.2) of children infected with other non-EV71 enteroviruses were positive by the IgM anti-EV71 assay. This cross-reaction was supposed to be due to the common epitopes among enteroviruses, and was mild as suggested by the lower S/CO values and the lower occurrence rate.

In conclusion, the data here presented show that the detection of IgM anti-EV71 by ELISA affords a reliable, convenient, and prompt diagnosis of EV71 infection. The whole assay takes 90 min using readily available ELISA equipment, is easy to perform with low cost, which made it suitable in clinical diagnosis as well as in public health utility.

**Acknowledgments**

We thank Dr. Per Jer Chen of Taiwan University for his fruitful discussion and providing some serum samples.

**Author Contributions**

Conceived and designed the experiments: FX SG JZ NX. Perfomed the experiments: FX QY SZ ZW TC YC DH YC. Analyzed the data: FX SG. Contributed reagents/materials/analysis tools: HW JN LL FZ SH. Wrote the paper: FX AEY JZ MHN.

---

### Table 2. Sensitivity of IgM anti-EV71 test at Different Times After Symptomatic Onset.

| Days after onset | Tested No. | Positive No. | Rate (%) (95% CI) | Mean S/CO (SD) |
|------------------|------------|--------------|-------------------|---------------|
| 1                | 20         | 18           | 90.0 (68.3–98.8)  | 4.66 (4.79)   |
| 2                | 25         | 22           | 88.0 (68.8–97.5)  | 6.00 (5.86)   |
| 3–4              | 43         | 39           | 90.7 (77.9–97.4)  | 6.90 (4.63)   |
| 5–10             | 53         | 51           | 96.2 (87.0–99.5)  | 11.92 (5.98)  |
| 11–20            | 43         | 42           | 97.7 (87.7–99.9)  | 16.41 (6.05)  |
| 21–30            | 13         | 13           | 100.0 (83.2–100.0)| 9.39 (6.17)   |
| 31–41            | 20         | 19           | 95.0 (78.9–99.9)  | 5.95 (4.37)   |
| Total            | 221        | 208          | 94.1 (90.2–96.8)  | 9.78 (6.84)   |

**Table 3. Specificity and cross-reactivity of IgM anti-EV71 in control subjects.**

| Ctrl Subjects                  | No. tested | No. positive | Specificity (%) (95% CI) |
|--------------------------------|------------|--------------|-------------------------|
| Enterovirus infected children  | 167        | 19           | 88.6 (82.8–93.0)        |
| CA16                           | 153        | 19           | 87.6 (81.3–92.4)        |
| Other enteroviruses            | 12         | 0            | 100 (73.5–100)          |
| Other Children                 | 2035       | 19           | 99.1 (88.6–99.4)        |
| Other infectious diseases       | 128        | 0            | 100 (97.2–100)          |
| Healthy children               | 1907       | 19           | 99.9 (98.5–99.4)        |
| Healthy adults                 | 807        | 1            | 99.9 (99.3–100)         |
| Rheumatoid factor (+)          | 20         | 0            | 100 (83.2–100)          |

**Table 2**. doi:10.1371/journal.pone.0011388.t002

**Table 3**. doi:10.1371/journal.pone.0011388.t003
References

1. Mcminn PC (2002) An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26: 91–107.
2. Perez-Velez CM, Anderson MS, Robinson CC, Mcfarland EJ, Nix WA, et al. (2007) Outbreak of neurologic enterovirus type 71 disease: a diagnostic challenge. Clin Infect Dis 45: 950–957.
3. Ooi EE, Phoon MC, Ishak B, Chan SH (2002) Seroepidemiology of human enterovirus 71, Singapore. Emerg Infect Dis 8: 995–996.
4. Yan JJ, Wang JR, Lin CC, Yang HR, Su IJ (2000) An outbreak of enterovirus 71 infection in Taiwan 1998: a comprehensive pathological, virological, and molecular study on a case of fulminant encephalitis. J Clin Virol 17: 13–22.
5. Li L, He Y, Yang H, Zhu J, Xu X, et al. (2005) Genetic characteristics of human enterovirus 71 and coxsackie virus A16 circulating from 1999 to 2004 in Shenzhen, People’s republic of China. J Clin Microbiol 43: 3835–3839.
6. Yang F, Ren L, Xiong Z, Li J, Xiao Y, et al. (2009) Enterovirus 71 outbreak in F. R. China, 2008. J Clin Microbiol 13: 2351–2352.
7. Qiu J (2008) Enterovirus 71 infection: a new threat to global public health? Lancet 7: 868–869.
8. Chang LY, Tsao VT, Hsia SH, Shih SR, Huang CG, et al. (2004) Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA 291: 222–227.
9. Lim KA, Benyesh-Melnick M (1960) Typing of virus by combination of antisera pools: Application to typing of enteroviruses. J Immunol 84: 309–317.
10. Tan EL, Yong LL, Qwah SH, Yeo WC, Chow VK, et al. (2000) Rapid detection of enterovirus 71 by real-time Taqman RT-PCR. J Clin Virol 42: 203–206.
11. Brown BA, Kilpatrick DR, Oberste S, Pallansch MA (2000) Serotype-specific identification of enterovirus 71 by PCR. J Clin Virol 16: 107–112.
12. Shih SR, Wang YW, Chen GW, Chang LY, Lin TY, et al. (2003) Serotype-specific detection of enterovirus 71 in clinical specimens by DNA microchip array. J Virol Methods 111: 55–60.
13. Tan EL, Chow VT, Kumarasirnge G, Lin RT, Mackay IM, et al. (2006) Specific detection of enterovirus 71 directly from clinical specimens using real-time RT-PCR hybridization probe assay. Mol Cell Probe 20: 135–140.
14. Tsao KC, Chan EC, Chang LY, Chang PY, Huang CG, et al. (2002) Responses of IgM for enterovirus 71 infection. J Med Virol 68: 574–580.
15. Wang SY, Lin TL, Chen HY, Lin TS (2004) Early and rapid detection of enterovirus 71 infection by an IgM-capture ELISA. J Virol Methods 119: 37–43.
16. Jin Q (2001) Medical molecular virology. Beijing: Science Press. 610 p.
17. Grandien M, Fosgren M, Ehrnst A (1995) Enterovirus. In: Lennette EH, ed. Laboratory Diagnosis of Viral Infections. New York: Marcel Dekker Inc. pp 351–364.
18. Ang LW, Koh BK, Chan KP, Chua LT, James L, et al. (2009) Epidemiology and control of hand, foot and mouth disease in Singapore, 2001–2007. Ann Acad Med Singapore 38: 106–112.
19. Chew KL, Takebe Y, Kumarazaman A (2009) Emerging and re-emerging viruses in Malaysia, 1997–2007. Int J Infect Dis 13: 307–318.